Septerna Highlights Business Progress
Septerna reports Q3 2026 results with planned Phase 1 trials for PTH1R agonist SEP-479 and oral TSHR NAM SEP-204, while maintaining a $565.2M cash position.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed